Our story

Founded in 2002, we are a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.

We leverage our deep expertise in oncology focused novel therapeutics for the benefit of cancer patients everywhere.

Our story

Founded in 2002, we are a clinical stage biotech company committed to the discovery and development of novel and effective therapeutics for the treatment of cancer.

We leverage our deep expertise in oncology focused novel therapeutics for the benefit of cancer patients everywhere.

Video of our Journey

Play Video

Our approach

We focus on developing innovative therapeutics addressing several hallmarks of cancer, leveraging our deep capabilities in science and building value added collaborations with leading companies globally.

drug development

Our impact

We have built comprehensive drug discovery and development capabilities, nurtured a growing team of passionate scientists, and collaborated with partners from across the world.

Media center

Get the latest updates from Aurigene in the news, conferences, events, and more.

clinical development

July 5, 2022

Aurigene Discovery Technologies Limited Announces Drug Discovery, Development, and Commercialization Partnership with EQRx

drug development

June 9, 2022

Olema Oncology and Aurigene Announce Exclusive Collaboration and License Agreement to Discover and Develop Novel Cancer Therapies

Get in touch with us:

Our publications

Explore our vast body of work in oncology research, innovative technology and therapeutics.

SMARCA2/4 degraders relieve the differentiation block in AML via changes in chromatin looping...

Paralogue selective p300 degraders induce synthetic lethality in pre-clinical models of CBP-deficient and...